Decoy Therapeutics Inc (DCOY) News & EventsDCOYDecoy Therapeutics Inc

Decoy Therapeutics D-MAV Candidate Shows Efficacy Against Ebola Virus

Decoy Therapeutics announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT platform to block coronavirus entry. In the same testing, the candidate also showed in vitro activity against Lassa fever virus, an arenavirus. Filovirus diseases, including Ebola, Marburg, and Lassa fever are among the conditions eligible for the FDA's tropical disease priority review voucher program, which supports development of treatments for diseases that lack sufficient commercial markets.

Selling Stockholders Plan to Sell 3.77M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.77M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Decoy Therapeutics Inc Trading Halted Due to Volatility

Decoy Therapeutics Inc trading halted, volatility trading pause